|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Valsartan#Overdosage]] |
| {{Valsartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Overdosage==
| |
| | |
| Limited data are available related to overdosage in humans. The most likely manifestations of overdosage would be [[hypotension]] and [[tachycardia]]; [[bradycardia]] could occur from parasympathetic (vagal) stimulation. Depressed level of consciousness, circulatory collapse and shock have been reported. If symptomatic [[hypotension]] should occur, supportive treatment should be instituted.
| |
| Diovan (valsartan) is not removed from the plasma by [[hemodialysis]].
| |
| | |
| Valsartan was without grossly observable adverse effects at single oral doses up to 2000 mg/kg in rats and up to 1000 mg/kg in marmosets, except for salivation and diarrhea in the rat and vomiting in the marmoset at the highest dose (60 and 31 times, respectively, the maximum recommended human dose on a mg/m2 basis). (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)<ref name="dailymed.nlm.nih.gov">{{Citace elektronické monografie | příjmení = | jméno = | titul = DIOVAN (VALSARTAN) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddba454-f3e6-43c2-a7a6-58365d297213 | vydavatel = | datum vydání = | datum aktualizace = | datum přístupu = 2014-02-24 }}</ref> | |
| | |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:Amides]]
| |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Biphenyls]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Novartis]]
| |
| [[Category:Tetrazoles]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |